Chlamydia trachomatis genital infection: Immunity and prospects for vaccine development

Inmunologia

Volumn 24, Issue 3, 2005, Pages 298-312

  Caro Vergara, M R ^a   Buendia Marin A J ^a   Del Rio Alonso L ^a   Cuello Gijon F ^a   Ortega Hernandez N ^a   Gallego Ruiz, M C ^a   Salinas Lorente, J ^a  

^a UNIVERSITY OF MURCIA   (Spain)

Author keywords

Chlamydia trachomatis; Chlamydophila abortus; Immunity; Immunopathology; Vaccines

Indexed keywords

BACTERIAL ANTIGEN; CHOLERA TOXIN; DNA VACCINE; MAJOR OUTER MEMBRANE PROTEIN; OLIGODEOXYNUCLEOTIDE; OUTER SURFACE PROTEIN A; UNCLASSIFIED DRUG;

CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CHLAMYDOPHILA; CHLAMYDOPHILA ABORTUS; CLINICAL TRIAL; DENDRITIC CELL; GENITAL TRACT INFECTION; HUMAN; IMMUNOBIOLOGY; NONHUMAN; REVIEW; SHEEP; VETERINARY MEDICINE; ZOONOSIS;

EID: 29444454731     PISSN: 02139626     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (134)

1. Everett KDE, Bush RM, Andersen AA. Emended description of the order Chlamydiales, proposal of Parachlamydiaceae fam. nov. and Simkaniaceae fam. nov., each containing one monotypic genus, revised taxonomy of the family Chlamydiaceae with description of five new species, and standards for identification of organisms. Int J Syst Bacteriol 1999;49:415-440.
2. Miller WC, Ford CA, Morris M, Handcock MS, Schmitz JL, Hobbs MM, et al. Prevalence of chlamydial and gonococcal infections among young adults in the United States. JAMA 2004;291:2229-2236.
3. Burstein GR, Gaydos CA, Diener-West M, Howell MR, Zenilman JM, Quinn TC. Incident Chlamydia trachomatis infections among inner-city adolescent females. JAMA 1998;280:521-526.
4. Hackstadt T. Chlamydia: Intracellular Biology, Pathogenesis, and Immunity. In: Stephens RS (Ed) ASM Press, Washington DC 1999; p101-138.
5. Dean D, Suchland RJ, Stramm, WE. Evidence for long-term cervical persistence of Chlamydia trachomatis by omp1 genotyping. J Infect Dis 2000;182:909-916.
6. Schachter J. Infection and disease epidemiology. In: Stephens RS (Ed.) ASM Press, Washington DC 1999; p139-169.
7. Wang SP, Grayston JT. Three new serovars of Chlamydia trachomatis: Da, Ia, and L2a. J. Infect Dis 1991;163:403-405.
8. Stephens RS, Sánchez-Pescador R, Wagar EA, Inouye C, Urdea MS. Diversity of Chlamydia trachomatis major outer membrane protein genes. J Bacteriol 1987;169:3879-3885.
9. Kelly KA, Rank RG. Identification of homing receptor that mediated the recruitment of CD4 T cells to the genital tract following intravaginal infection with Chlamydia trachomatis. Infect Immun 1997;65:5198-5208.
10. Register KB, Morgan PA, Wyrick PB. Interaction between Chlamydia spp. and human polymorphonuclear leukocytes in vitro. Infect Immun 1986;52:664-670.
11. Barteneva NI, Theodor I, Peterson EM, De la Maza LM. Role of neutrophils in controlling early stages of a Chlamydia trachomatis infection. Infect Immun 1996;64:4830-4833.
12. Tseng CK, Rank RG. Role of NK cells in early host response to Chlamydial genital infection. Infect Immun 1998;66:5867-5875.
13. Williams DM, Grubbs BG, Kelly K, Pack E, Rank RG. Role of gamma-delta T cells in murine Chlamydia trachomatis infection. Infect Immun 1996;64:3916-3919.
14. Yang X, Hayglass KT, Brunham RC. Genetically determined differences in IL-10 and IFN-g responses correlate with clearance of Chlamydia trachomatis mouse pneumonitis infection. J Immunol 1996;156:4338-4344.
15. Johansson M, Ward ME, Lycke N. B-cell-deficient mice develop complete immune protection against genital tract infection with Chlamydia trachomatis. Immunology 1997;92:422-428.
16. Yang X, Hayglass KT, Brunham RC. Different roles are played by ab and gd T cells in acquired immunity to Chlamydia trachomatis pulmonary infection. Immunology 1998;94:469-475.
17. Bailey RL, Kajbaf M, Whittle HC, Ward ME, Mabey DC. The influence of local antichlamydial antibody on the acquisition and persistence of human ocular chlamydial infection: IgG antibodies are not protective. Epidemiol Infect 1993;111:315-324.
18. Holland MJ, Bailey RL, Con way DJ, Culley F, Miranpuri G, Byrne GI, et al. T helpher type-1 (Th1)/Th2 profiles of peripheral blood mononuclear cells (PBMC): responses to antigens of Chlamydia trachomatis in subjects with severe trachomatous scarring. Clin. Exp Immunol 1996;105:429-435.
19. Holland MJ, Bailey RL, Hayes LJ, Whittle HC, Mabey DC. Conjunctival scarring in trachoma is associated with depressed cell mediated immune responses to Chlamydial Antigens. J Infect Dis 1993;168:1528-1531.
20. Hauser CJ. Cultured epidermal Langerhans cells activate effector T cells for contact sensitivity. J Invest Dermatol 1990;95:436-440.
21. Fong TAT, Mosmann TR. The role of IFN-gamma in delayed type hypersensitivity mediated by Th1 clones. J Immunol 1989;143:2887-2893.
22. Yang X, Gartner J, Zhu L, Wang S, Brunham RC. IL-10 gene knockout mice show enhanced protective Th1-like immune responses and absence of granuloma formation following Chlamydia trachomatis lung infection. J Immunol 1999;162:1010-1017.
23. Muller KM, Jaunin F, Masouye I, Saurat JH, Hauser CJ. Th2 cells mediate IL-4-dependent local tissue inflammation. J Immunol 1993;150:5576-5584
24. Brunham RC, Rey-Ladino J. Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine. Nature Rev Immunol 2005;5:149-161.
25. Border WA, Ruoslahti E. Transforming growth factor-β1 induces extracellular matrix formation in glomerulonephritis. Cell Differ Dev 1990;32:425431.
26. Border WA, Noble NA, Yamamoto T, Harper JR, Yamaguchi Y, Pierschbacher MD, et al. Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 1992;360:361-364.
27. Brokelman T, Limper AH, Colby TV, McDonald JA. Transforming growth factor β1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci USA 1991;88:6642-6646.
28. Waalen K, Forre O, Teigland J, Natvig JB. Characteristics of human rheumatoid synovial and normal blood dendritic cells. Retention of class II major histocompatibility complex antigens and accessory function after short-term culture. Scand J Immunol 1987;26:525-533.
29. Masahiro Y, Wang XH, Ohmen JD, Uyemura K, Rea TH, Bloom BR, et al. Cytokine patterns of immunologically mediated tissue damage. J Immunol 1992;149:1470-1475.
30. Allen JE, Maizels RM. Th1-Th2: reliable paradigm or dangerous dogma? Immunol Today 1997;18:387-392.
31. Perry LL, Su H, Feilzer K, Messer R, Hughes S, Whitmore W, et al. Differential sensitivity of distinc Chlamydia trachomatis isolates to IFN-γ-mediated inhibition. J Immunol 1999;162:3541-3548.
32. Johansson M, Schon K, Ward M, Lycke N. Studies in knockout mice reveal that anti-chlamydial infection requires Th1 cells producing gamma-interferon: is this true for humans? Scand J Immunol 1997;46:546-552.
33. Iwasaki A, Medhitov R. Toll like receptor control of the adaptive immune responses. Nature Immunol 2004;5:987-995.
34. Ojcius DM, Bravo de Alba Y, Kanellopoulus JM, Hawkins RA, Kelly KA, Rank RG, et al. Internalization of Chlamydia by Dendritic Cells and Stimulation of Chlamydia-Specific T Cells. J Immunol 1998;160:1297-1303.
35. Knight SC, Iqball S, Woods C, Stagg A, Ward ME, Tuffrey M. A peptide of Chlamydia trachomatis shown to be a primary T-cell epitope in vitro induces cell-mediated immunity in vivo. Immunology 1995;85:8-15.
36. Lu H, Zhong G. Interleukin-12 production is required for chlamydial antigen-pulsed dendritic cells to induce protection against live Chlamydia trachomatis infection. Infect Immun 1999;67:1763-1769.
37. Shaw KH, Grund VR, Durling L, Caldwell HD. Expresion of genes encoding Th1 cell activating cytokines and lymphoid homing chemokines by Chlamydia-pulsed dendritic cells correlates with protective immunizing efficacy. Infect Immun 2001;69:4667-4672.
38. Kalinski P, Schuitemaker JH, Hilkens CM, Wierenga EA, Kapsenberg ML. Final maturation of dendritic cells is associated with impaired responsiveness to IFN-gamma and to bacterial IL-12 during the interaction with Th cells. J Immunol 1999;162:3231-3236.
39. Rey-Ladino J, Kasra M, Koochesfahani ML, Zaharik CS, Brunham RC. A live inactivated Chlamydia trachomatis mouse pneumonias strain induces the maturation of dendritic cells that are phenotipically and immunologically distinct. Infect Immun 2005;73:1568-1577.
40. Loomis WP, Starnbach MN. T cell responses to Chlamydia trachomatis. Curr Opin Microbiol 2002;5:87-91
41. Ramsey KH, Rank RG. Resolution of chlamydial genital infection with antigen-specific T-lymphocyte lines. Infect Immun 1991;59:925-931.
42. Starnbach MN, Bevan MJ, Lampe MF. Protective cytotoxic T lymphocytes are induced during murine infection with Chlamydia trachomatis. J Immunol 1994;153:5183-5189.
43. Starnbach MN, Loomis WP, Ovendale P, Regan D, Hess B, Alderson MR, et al. An inclusion membrane protein from Chlamydia trachomatis enters the MHC class I pathway and stimulates a CD8 (+) T cell response. J Immunol 2003;171:4742-4749.
44. + cells. Med Microbiol Immunol 1998;187:71-78.
45. Ortiz L, Angevine S, Kim SK, Watkins D, DeMArs R. T cell epitopes in variable segments of Chlamydia trachomatis major outer membrane protein elicit serovar specific immune responses in infected humans. Infect Immun 2000;68:1719-1723.
46. Goodall JC, Beacock-Sharp H, Deane KH, Gaston JS. Recognition of the 60 kilodalton cysteine-rich outer membrane protein OMP2 by CD4(+) T cells from humans infected with Chlamydia trachomatis. Clin Exp Immunol 2001;126:488-493.
47. + T lymphocytes by screening an expression library. Eur J Immunol 2001;31:1513-1522.
48. Deane KH, Jecock RM, Pearce JH, Gaston JS. Identification and characterization of a DR4-restricted T cell epitope within Chlamydia heat shock protein 60. Clin Exp Immunol 1997;109:439-445.
49. Holland MJ, Conway DJ, Blanchard TJ, Mahdi OM, Bailey RL, Whittle HC, et al. Synthetic peptides based on Chlamydia trachomatis antigens identify cytotoxic T lymphocyte responses in subjects from a trachoma-endemic population. Clin Exp Immunol 1997;107:44-49.
50. + CTLs with HLA class I tetramers. J Immunol 2000;165:7285-7292.
51. Cotter TW, Ramsey KH, Miranpuri GS, Poulsen CE, Byrne GI. Dissemination of Chlamydia trachomatis chronic genital tract infection in gamma interferon gene knockout mice. Infect Immun 1997;65:2145-2152.
52. Ito JI, Lyons JM. Role of gamma interferon in controlling murine chlamydial genital tract infection. Infect Immun 1999;67:5518-5521.
53. Johansson MK, Schon K, Ward M, Lycke N. Genital tract infection with Chlamydia trachomatis fails to induce protective immunity in gamma interferon receptor-deficient mice despite a strong local immunoglobulin response. Infect Immun 1997;65:1032-1044.
54. Perry LL, Feilzer K, Caldwell HD. Immunity to Chlamydia trachomatis is mediated by T helper 1 cells trough IFN-γ-dependent and independent-pathways. J Immunol 1997;158:3344-3352.
55. Rottenberg ME, Gigioti-Rothfuchs A, Wigzell A. The role of IFN-gamma in the outcome of chlamydial infection. Curr Opi Immunol 2002;14:444-451.
56. Holtmann H, Shemer-Avni Y, Wessel K, Sarov I, Wallach D. Inhibition of growth of Chlamydia trachomatis by tumor necrosis factor is accompanied by increased prostanglandin synthesis. Infect Immun 1990;58:3168-3172.
57. Morrison RP, Feilzer K, Tumas DB. Gene knockout mice establish a primary protective role for major histocompatibility complex class II-restricted responses in Chlamydia trachomatis genital tract infection. Infect Immun 1995;63:4661-4668.
58. + T cells. Infect Immun 2001;69:2643-2649.
59. + T cells. Infect Immun 2000;68:6979-6987.
60. + T cells play a significant role in adoptive immunity to Chlamydia trachomatis infection of the mouse genital tract. Infect Immun 1995;63:3302-3308.
61. Beatty WL, Belanger TA, Desai AA, Morrison RP, Byrae GI. Tryptophan depletion as a mechanism of γ-interferon-mediated chlamydial persistence. Infect Immun 1994;62:3705-3711.
62. Caldwell HD, Wood H, Crane D, Bailey R, Jones RB, Mabey et al., Polymorphisms in Chlamydia trachomatis trptophan synthasa genes differentiate between genital and ocular isolates. J Clin Invest 2003;111:1757-1769.
63. Igietseme JU, Perry LL, Ananaba GA, Uriri M, Ojior OO, Kumar SH, et al. Chlamydial infection in inducible nitric oxide synthasa knockout mice. Infect Immun 1998;66:1282-1286.
64. + T cells show two patterns of antigen recognition. Infect Immun 2004;72:4357-4367.
65. Morrison RP, Caldwell HD. Immunity to murine Chlamydial genital infection. Infect Immun 2002;70:2741-2751.
66. Igietseme JU, Black CM, Caldwell HD. Chlamydia vaccine: strategies and status. BioDrugs 2002;16:19-35.
67. Moore T, Ekworomadu CO, Eko FO, MacMillan L, Ramey K, Ananaba GA et al. Fc receptor mediated antibody regulation of T cell immunity against intracellular pathogens. J Infect Dis 2003;188:617-624.
68. Igietseme Ju, Eko FO, He Q, Black CM. Antibody regulation of T cell immunity: implications for vaccine strategies against intracellular pathogens. Expert Rev Vaccines 2004;3:23-24.
69. Tagliabue A, Boraschi D, Villa L, Keren F, Lowell GH, Rappuoli R, et al. IgA-dependent cell-mediated activity aginst enteropathogenis bacteria: distribution, specificity, and characterization of the effector cells. J Immunol 1984;133:988-992.
70. Tagliabue A, Boraschi D, Villa L, Geri V, De Gori V, Nencioni L. Natural anti-bacterial activity against Salmonella typhi by human T4+ lymphocytes armed with IgA antibodies. J Immunol 1985;135:4178-4182.
71. Tabiglue A, Villa L, De Magistris MT, Romano M, Silvestri S, Boraschi D, et al. IgA- driven T cell mediated anti bacterial immunity in man after live oral Ty 21a vaccine. J Immunol 1986;137:1504-1510.
72. Linton PJ, Harbetston J, Bradley LM. A critical role for B cells in the development of memory CD4 cells. J Immunol 2000;165:5558-5565.
73. Guseva NV, Stephen TK, Whittimore JD, Wyrick PB. Primary cultures of female swine genital epithelial cells in vitro: a new approach for the study of hormonal modulation of Chlamydia infection. Infect Immun 2003;71:4700-4710.
74. Kozlowski PA, Williams SB, Lynch RM, Flanigan TP, Patterson RR, Cu-Uvin S, et al. Differential induction of mucosal and systemic antibody responses in women after nasal, rectal or vaginal immunization: influence of the menstrual cycle. J Immunol 2002;169:566-574.
75. Mahdi OS, Byrne GI, Kalayoglu M. Emerging strategies in the diagnosis, prevention and treatment of chlamydial infections. Expert Opin Therapeutic Patients 2001;1253-1265.
76. De la Maza LM, Peterson EM. Vaccines for Chlamydia trachomatis infections. Curr Opin Investig Drugs 2002;3:980-986.
77. + T cells recognize an inclusion membrana-associated protein from the vacuolar pathogen Chlamydia trachomatis. Proc Natl Acad Sci USA 2001;98:1160-1165.
78. + T cells recognize the 60kDa cysteie-rich outer membrane protein from Chlamydia trachomatis. J Immunol 2004;173:6905-6913.
79. Kim SK, DeMars R. Epitope dusters in the major outer membrane protein of Chlamydia trachomatis. Curr Opi Immunol 2001;13:429-436.
80. Clifton DR, Fields KA, Grieshaber SS, Dooley CA, Fischer ER, Mead DJ, et al. A chlamydial type III translocated protein is tyrosine-phosphorylated at the site of entry and associated with recruitment of actin. Proc Natl Acad Sci USA 2004;101:10166-10171.
81. Rockey DD, Rosquit JL. Protein antigens of Chlamydia psittaci present in infected cells but not detected in the infectious elementary body. Infect Immun 1994;62:106-112.
82. Grayston JT, Wang SP. The potential for vaccine against infection of the genital tract with Chlamydia trachomatis. Sex Transm Dis 1978;5:73-77.
83. Morrison RP, Belland RJ, Lyng K, Caldwell HD. Chlamydial disease pathogenesis. The 57-kD chlamydial hypersensitivity antigen is a stress response protein. J Exp Med 1989;170:1271-1283.
84. Dong-Ji Z, Yang X, Shen C, Lu H, Murdin A, Brunham RC. Priming with Chlamydia trachomatis major outer membrane protein (MOMP) DNA followed by MOMPISCOM boosting enhances protection and is associated with increased immunoglobulin A and Th1 cellular immune response. Infect Immun 2000;68:3074-3078.
85. Pal S, Barnhart KM, Wei Q, Abai AM, Peterson EM, De la Maza LM. Vaccination of mice with DNA plasmids coding for the Chlamydia trachomatis major outer membrane protein elicits an immune response but fails to protect against a genital challenge. Vaccine 1999;17:459-465.
86. Babiuk LA, Pontarollo R, Babiuk S, Loehr B, Van Drunen Little-van den Hurk S. Induction of immune responses by DNA vaccines in large animals. Vaccine 2003;21:649-658.
87. Kalman S, Mitchell W, Marathe R, Lammel C, Fan J, Hyman RW, et al. Comparative genomes of Chlamydia pneumonie and C. trachomatis. Nat Genet 1999;21:385-389.
88. Read TD, Brunham RC, Shen C, Gill SR, Heidelberg JF, White O, et al. Genome sequence of Chlamydia trachomatis MoPn and Chlamydia pneumonie AR39. Nucleic Acids Res 2000;28:1397-1406.
89. Stephens RS. Chlamydial Genomics and Vaccine Antigen Discovery. J Infect Dis 2000;(Suppl)181:521-523.
90. Belland RJ, Scidmore MA, Crane DD, Hogan MD, Whitmire W, McClarty G, et al. Chlamydia trachomatis cytotoxicity associated with complete and partial cytotoxin genes. Proc Natl Acad Sci USA 2001;98:13984-13989.
91. Rockey DD, Stephens RS. Genome sequencing and our understanding of chlamydiae. Infect Immun 2000;68:5437-5479.
92. Kawa DE, Stephens RS. Antigenic topology of chlamydial PorB protein and identification of targets for immune neutralization of infectivity. J Immunol 2002;168:5184-5191.
93. Gregoriadis G, Bacon A, Caparros-Wanderley W, McCormack B. A role for liposomes in genetic vaccination. Vaccine 2002;Suppl 5:B1-B9.
94. Moingeon P, Haensler J, Lindberg A. Towards the rational design of Th1 adjuvants. Vaccine 2001;19:4363-4372.
95. Igietseme JU, Murdin A. Induction of protective immunity against Chlamydia trachomatis genital infection by a vaccine based on major outer membrane protein-lipophilic immune response-stimulating complexes. Infect Immun 2000;68:6798-6806.
96. Stagg AJ. Vaccines against Chlamydia: approaches and progress. Mol Med Today 1998;4:166-173.
97. Brunham RC, Zhang DJ. Transgene as vaccine for Chlamydia. Am Heart J 1999;138:S519-S522.
98. Pal S, Luke CJ, Barbour AG, Peterson EM, De la Maza LM. Immunization with the Chlamydia trachomatis major outer membrane protein, using the outer surface protein A of Borrelia burgdorferi as an adjuvant, can induce protection against a chlamydial genital challenge. Vaccine 2003;21:1455-1465.
99. Eko FO, Lubitz W, McMillan L, Ramey K, Moore TT, Ananaba GA, et al. Recombinant Vibrio cholerae ghosts as a delivery vehicle for vaccination against Chlamydia trachomtis. Vaccine 2003;21:1694-1703.
100. Szostak MP, Hensel A, Eko FO, Klein R, Auer T, Mader H, et al. Bacterial ghosts: non living candidate vaccines. J Bacteriol 1996;44:17-161.
101. Su H, Messer R, Whitmore W, Fischer E, Ports JC, Caldwell HD. Vaccination against Chlamydial genital tract infection after immunization with dendritic cells pulsed ex vivo with non viable Chlamydiae. J Exp Med 1998;188:809-818.
102. Igietseme JU, Ananaba GA, Bolier J, Bowers S, Moore T, Belay T, et al. Supressión of endogeneous IL-10 gene expression in dendritic cells enhances antigen presentation for enhanced specific Th1 induction: potencial for cellular vaccine development. J Immunol 2000;164:4212-4219.
103. Longbottom D, Coulter LJ. Animal chlamydioses and zoonotic implications. J Comp Pathol 2003;128:217-244.
104. Buxton D. Chlamydia psittaci of ovine origen: an especial risk to pregnant women. In: Chlamydial diseases of rumiants. Ed. Aitken ID, Commission of the European Communities, Luxembourg 1986. p:121.
105. Hyde SR, Benirscke K. Gestational psittacosis: case report and literature review. Modern Pathol 1997;10:602-607.
106. Entrican G, Buxton D, and Longbottom D. Chlamydial infection in sheep: immune control versus fetal pathology. J R Soc Med 2001;94:273-277.
107. De Sa, C, Souriau A, Bernard F, Salinas J, Rodolakis A. An oligomer of the major outer membrane protein of Chlamydia psittaci is recogniced by monoclonal antibodies which protect mice from abortion. Infect Immunol 1995;63:4912-4916.
108. Buendia AJ, Sánchez J, Martínez MC, Cámara P, Navarro JA, Rodolakis A, et al. Kinetics of infection and effects on placental cell population in murine model of Chlamydia psittaci-induced abortion. Infect Immun 1998;66:2128-2134.
109. + T cell in a mouse model. J Comp Pathol 2000;132:171-181.
110. Yelamos J, Buendía AJ, Ortega N, Monreal Y, Gallego MC, Sanchez J, et al. Genetic and pharmacological inhibition of poly (ADP-ribose) polymerase-1 interferes in the chlamydial life cycle. Biochem Biophys Res Comm 2004;324:840-848.
111. Navarro JA, García de la Fuente JN, Sánchez J, Martínez CM, Buendía AJ, Gutierrez-Marín CB, et al. Kinetics of infection and effects on the placenta of Chlamydophila abortus in experimentally infected pregnant ewes. Vet Pathol 2004;41:498-505.
112. Buendía AJ, Montes de Oca R, Navarro JA, Sánchez J, Cuello F, Salinas J. Role of polymorphonuclear neutrophils in a murine model of Chlamydia psittaci-induced abortion. Infect Immun 1999;67:2110-2116.
113. + T cells in the liver in a pregnant mouse model of Chlamydophila abortus (Chlamydia psittaci Serotype 1) infection. Infect Immun 2000;68:1746-1751.
114. Montes de Oca R, Buendía AJ, Sánchez J, Del Río L, Seva J, Navarro JA, et al. Limited role of polymorphonuclear neutrophils in a pregnant mouse model of secondary infection by Chlamydophila abortus (Chlamydia psittaci serotype 1). Microbiol Pathol 2000;29:319-327.
115. Buendía AJ, Martínez CM, Ortega N, Del Río L, Caro MR, Gallego MC, et al. Natural Killer (NK) cells play a critical role in the early innate immune response to Chlamydophila abortus infection in mice. J Comp Pathol 2004;130:48-57.
116. Del Río L, Buendía AJ, Sánchez J, Gallego MC, Caro MR, Ortega N, et al. Endogenous IL-12 is not required for resolution of Chlamydophila abortus (Chlamydia psittaci serotype 1) Infection in mice. Infect Immun 2001;69:4808-4815.
117. Martinez, CM, Buendía AJ, Ortega N, Sanchez J, Caro MR, Gallego MC, et al. Differential importance of CD4 and CD8 T cells in the resolution of Chlamydophila abortus primary infection in mice. J Comp Pathol 2005 (Submitted for publication).
118. Buendía AJ, Del Río L, Ortega N, Sánchez J, Gallego MC, Caro MR, et al. B-cell-defident mice show an exacerbated inflammatory response in a model of Chlamydophila abortus infection. Infect Immun 2002;70:6911-6918.
119. Entrican G. Immune regulation during pregnancy and host-pathogen interactions in infectious abortion. J Comp Pathol 2002;126:79-94.
120. McEwen AD, Stamp JT, Littlejohn AI. Enzootic abortion of ewes II. Immunisation and infection experiments. Vet Rec 1951;63:197-201.
121. Aitken ID, Clarkson MJ, Linklater K. Enzootic abortion in ewes. Vet Rec 1990;126:136-138.
122. Jones GE, Jones KA, Machell J, Brebner J, Anderson IE, How S. Efficacy trials with tissue-culture grown, inactivated vaccines against chlamydial abortion in sheep. Vaccine 1995;13:715-723.
123. Rodolakis A, Souriau A. Responses of ewes to temperature-sensitive mutants of Chlamydia psittaci var. ovis obtained by NTG mutagenesis. Ann Rech Vet 1983;14:155-161.
124. Chalmers WS, Simpson J, Lee SJ, Baxendale W. Use of live chlamydial vaccine to prevent ovine enzootic abortion. Vet Rec 1997;141:63-67.
125. Vretou E, Psarrou E, Kaisar M, Vlisidou I, Salti-Montesanto V, Longbottom D. Identification of protective epitopes by sequencing of the major outer membrane protein gene of variant strain of Chlamydia psittaci serotype 1 (Chlamydophila abortus). Infect Immun 2001;69:607-612.
126. Herring AJ, Jones GE, Dunbar SM. Recombinant vaccines against Chlamydia psittaci -an overview of results using expression and a new approach using a plan virus «overcoat» system. In: Stephens RS, Byrne GI, Christiansen G, Clarke IN, Grayston JT, et al. Rank RC. (Eds). Proc Ninth Int Sym Hum Chlam Infect 1998;434-437.
127. Hechard C, Grepinet O. DNA vaccination against Chlamydiaceae: current status and perspectives. Vet Res 2004;35:149-161.
128. Rodolakis A, Gestin L, Bertin A. Mèthode de controle des vaccines contre la chlamydiose abortive ovine utilisant la souris gestante. Ann Rech Vét 1981;12:371-377.
129. Rodolakis A, Salinas J, Papp J. Recent advances on ovine chlamydial abortion. Vet Res 1998;29:275-288.
130. Caro MR, Ortega N, Buendía AJ, Gallego MC, Del Río L, Cuello F, et al. Protection conferred by commercially available vaccines against Chlamydophila abortus in a mouse model. Vet Rec 2001;149:492-493.
131. Caro MR, Ortega N, Buendía AJ, Gallego MC, Del Rio L, Cuello F, et al. Relationship between the immune response and protection conferred by new designed inactivated vaccines against ovine enzootic abortion in a mouse model. Vaccine 2003;21:3126-3136.
132. Caro MR, Buendía AJ, Ortega N, Gallego MC, Martinez CM, Cuello F, et al. Influence of the Th2 immune response established by Nippostronyilus brasiliensis infection on the protection offered by different vaccines against Chlamydophila abortus infection. Vet Res Comm 2005;29:51-59.
133. García de la Fuente JN, Gutierrez-Martín CB, Ortega N, Rodríguez Ferri EF, del Río ML, Gonzalez OR, et al. Efficacy of different commercial and new inactivated vaccines against ovine enzootic abortion. Vet Microbiol 2004;100:65-76.
134. Thomson NR, Yeats C, Bell K, Holden MT, Bentley SD, Livingstone M, et al. The Chlamydophila abortus genome sequence reveals an array of variable proteins that contribute to interspecies variation. Genome Res 2005;15:629-640.